The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer.

Al-Rawi DH, Rusk N, Friedman CF
Clinical cancer research : an official journal of the American Association for Cancer Research · 2023 · doi:10.1158/1078-0432.ccr-23-0048 · PMID:36826422 · PMC10159911
OA: closed
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-07 ⓘ

Homologous recombination deficient ovarian tumors did not show improved progression-free survival with atezolizumab addition in a substudy of the IMagyn050 trial.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-06T09:34:12.023084+00:00